Key facts
- More than 120 strategic enterprises have established or expanded operations in Hong Kong.
- The latest batch of 22 enterprises includes leaders in pharmaceuticals, AGI, and advanced microprocessors.
- Collectively, these companies are projected to bring approximately $73 billion in investment.
- These companies are expected to create about 25,000 job opportunities in high-end R&D and management.
More than 120 strategic enterprises have established or expanded operations in Hong Kong, with the latest batch of 22 companies including global leaders in pharmaceuticals, artificial general intelligence (AGI), and advanced microprocessor manufacturing. The Office for Attracting Strategic Enterprises (OASES) announced the new cohort on April 20, following a previous announcement on October 9 that welcomed 18 enterprises.
Collectively, these companies are projected to bring approximately HK$73 billion in investment and create about 25,000 job opportunities in high-end research and development (R&D) and management positions. The earlier batch of 18 enterprises was expected to bring HK$60 billion in investment and create 22,000 jobs.
Financial Secretary Paul Chan stated that these enterprises strengthen Hong Kong's innovation ecosystem, with many forming partnerships with local universities and research institutions. Companies like GlaxoSmithKline and Roche highlighted Hong Kong's position in the Greater Bay Area as a key advantage for connecting with mainland China and expanding operations.